Accustem Sciences (ACUT) Accounts Payables (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Accounts Payables of $737549.0 for Q1 2026, down 13.13% year-over-year from $849071.0 in Q1 2025, and up 4.79% quarter-over-quarter from $703812.0 in Q4 2025.
Accustem Sciences (ACUT) Accounts Payables (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Accounts Payables for 6 consecutive years, with $737549.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 13.13% year-over-year to $737549.0; the TTM figure through Mar 2026 stood at $737549.0 (down 13.13% YoY), while the FY2025 annual figure was $703812.0, down 12.53% from the prior year.
- Accounts Payables advanced to $737549.0 in Q1 2026 per ACUT's latest filing, from $703812.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $923191.0 in Q3 2025 and bottomed at $108961.0 in Q2 2022.
- Historically, Accounts Payables has averaged $571636.2 across 5 years, with a median of $649480.0 in 2024.
- Annual changes were most pronounced in 2022 — Accounts Payables dropped 19.77% — and 2023, when it jumped 251.29%.
- Accustem Sciences' Accounts Payables stood at $311834.0 in 2022, then surged by 85.48% to $578378.0 in 2023, then soared by 39.12% to $804615.0 in 2024, then fell by 12.53% to $703812.0 in 2025, then rose by 4.79% to $737549.0 in 2026.
- Business Quant data shows ACUT's Accounts Payables at $737549.0 in Q1 2026, $703812.0 in Q4 2025, and $923191.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Accustem Sciences | 3.54 Mn | 3.52 Mn | - | 615,592.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 737,549.00 |
| Dec 31, 2025 | 703,812.00 |
| Sep 30, 2025 | 923,191.00 |
| Jun 30, 2025 | 859,925.00 |
| Mar 31, 2025 | 849,071.00 |
| Dec 31, 2024 | 804,615.00 |
| Sep 30, 2024 | 790,241.00 |
| Jun 30, 2024 | 744,693.00 |
| Mar 31, 2024 | 649,480.00 |
| Dec 31, 2023 | 578,378.00 |
| Sep 30, 2023 | 432,363.00 |
| Jun 30, 2023 | 382,769.00 |
| Mar 31, 2023 | 307,075.00 |
| Dec 31, 2022 | 311,834.00 |
| Sep 30, 2022 | 154,889.00 |
| Jun 30, 2022 | 108,961.00 |
| Mar 31, 2022 | 378,970.00 |
| Dec 31, 2021 | 388,681.00 |